Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Cloud Computing Framework

Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Cloud Computing Framework

Charalampos Tsirmpas (Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, Division of Information Transmission Systems and Material Technology, National Technical University of Athens, Athens, Greece), Kostas Giokas (Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, Division of Information Transmission Systems and Material Technology, National Technical University of Athens, Athens, Greece), Dimitra Iliopoulou (Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, Division of Information Transmission Systems and Material Technology, National Technical University of Athens, Athens, Greece) and Dimitris Koutsouris (Biomedical Engineering Laboratory, School of Electrical and Computer Engineering, Division of Information Transmission Systems and Material Technology, National Technical University of Athens, Athens, Greece)
Copyright: © 2012 |Pages: 12
DOI: 10.4018/ijrqeh.2012100101
OnDemand PDF Download:
$30.00
List Price: $37.50

Abstract

Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) are two non-invasive techniques that are increasingly being used to identify and quantify biochemical markers associated with certain diseases, e.g., choline in the case of cancer. The associating of MRI/MRS images, patient’s electronic health record, genome information, and environmental factors increase the precision of diagnosis and treatment. The authors present a collaboration framework based on Cloud Computing which allows analysis of MRI/MRS data based on advanced mathematical tools, advanced combination, and link discovery between different data types, so as to increase the precision and consequently avoid non-appropriate therapy and treatment plans.
Article Preview

Prostate And Breast Cancer

Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer death among men in the U.S. In 2010, it accounted for 217,000 (28% of the total) new cases, and 32,000 deaths. The incidence for prostate cancer has fluctuated considerably in 1975-1995, and much less since. The reasons for this are not clear, with studies on screening producing conflicting results (Eheman et al., 2012; Jemal, Siegel, Xu, & Ward, 2010)

In Europe the incidence is lower than that of the U.S. and Canada; however, there exist large disparities between different European countries. In the developing world the incidence rates are significantly lower, due to the fact that prostate cancer is a disease of the elderly. The late onset of the disease and its slow progression combined with the low life expectancy in the developing world make prostate cancer less of a concern in these countries. However, the aging of the population in the Western world, the rising of the middle class in countries such as China, and the associated increase in life expectancy suggest that prostate cancer will be a major health concern in the 21st century (Quinn & Babb, 2002).

Complete Article List

Search this Journal:
Reset
Open Access Articles: Forthcoming
Volume 7: 4 Issues (2018): 1 Released, 3 Forthcoming
Volume 6: 4 Issues (2017)
Volume 5: 4 Issues (2016)
Volume 4: 4 Issues (2015)
Volume 3: 4 Issues (2014)
Volume 2: 4 Issues (2013)
Volume 1: 4 Issues (2012)
View Complete Journal Contents Listing